title: Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind study.
abstract: Forty cats with previously untreated, histologically confirmed mammary gland adenocarcinoma received a radical mastectomy of the affected mammary chain(s). All cats were stratified according to clinical stage and randomized to receive either weekly intravenous liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or placebo (lipid-equivalent) for eight consecutive weeks in this double-blind study. Thirty-six of the 40 cats were available for follow-up. No significant differences in either disease-free interval or survival were found as a result of treatment. Cats with clinical stage II disease had a statistically significantly longer disease-free interval (p < 0.02), and overall survival (p < 0.005) when compared with clinical stage III cats.
authors.affiliation: University of Florida, College of Veterinary Medicine, Gainesville 32610-0126, USA.
authors.forename: L E
authors.initials: LE
authors.lastname: Fox
authors.forename: E G
authors.initials: EG
authors.lastname: MacEwen
authors.forename: I D
authors.initials: ID
authors.lastname: Kurzman
authors.forename: R R
authors.initials: RR
authors.lastname: Dubielzig
authors.forename: S C
authors.initials: SC
authors.lastname: Helfand
authors.forename: D M
authors.initials: DM
authors.lastname: Vail
authors.forename: W
authors.initials: W
authors.lastname: Kisseberth
authors.forename: C
authors.initials: C
authors.lastname: London
authors.forename: B R
authors.initials: BR
authors.lastname: Madewell
authors.forename: C O
authors.initials: CO
authors.lastname: Rodriguez
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000662:veterinary*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D002415:Cats; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D007262:Infusions, Intravenous; D008081:Liposomes; D008297:Male; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015409:Mastectomy, Radical; D009367:Neoplasm Staging; D010714:Phosphatidylethanolamines / Q000627:therapeutic use*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; D010714:Phosphatidylethanolamines; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine